Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial

International Journal of Clinical Oncology

Volumn 20, Issue 5, 2015, Pages 905-912

  Komatsu, Yoshito ^a   Doi, Toshihiko ^b   Sawaki, Akira ^c   Kanda, Tatsuo ^d   Yamada, Yasuhide ^e   Kuss, Iris ^f   Demetri, George D ^g   Nishida, Toshirou ^b  

^a HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^d NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f BAYER PHARMA AG   (Germany)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Gastrointestinal stromal tumor; Hand foot syndrome; Hypertension; Japanese; Regorafenib

Indexed keywords

ASPARTATE AMINOTRANSFERASE; IMATINIB; PLACEBO; REGORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; INDOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER STAGING; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; JAPANESE (PEOPLE); MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; ORAL MUCOSITIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; ETHNOLOGY; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; MIDDLE AGED; PATHOLOGY; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMATINIB MESYLATE; INDOLES; MIDDLE AGED; PHENYLUREA COMPOUNDS; PYRIDINES; PYRROLES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84942985271     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-015-0790-y     Document Type: Article

References (20)

1. Blay JY, Le Cesne A, Cassier PA et al (2012) Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. Discov Med 13:357–367
2. Nilsson B, Bumming P, Meis-Kindblom JM et al (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population-based study in western Sweden. Cancer (Phila) 103:821–829
3. Tryggvason G, Gislason HG, Magnusson MK et al (2005) Gastrointestinal stromal tumors in Iceland, 1990–2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 117:289–293
4. Nishida T, Takahashi T, Miyazaki Y (2009) Gastrointestinal stromal tumor: a bridge between bench and bedside. Gastric Cancer 12:175–188
5. Corless CL, Barnett CM, Heinrich MC (2011) Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 11:865–878
6. Demetri GD, Benjamin RS, Blanke CD et al (2007) NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST): update of the NCCN clinical practice guidelines. J Natl Comp Canc Netw 5:S1–S29
7. Blay JY (2011) A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST. Cancer Treat Rev 37:373–384
8. Demetri GD, von Mehren M, Antonescu CR et al (2010) NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Comp Canc Netw 8(suppl 2):S1–S41
9. Wilhelm SM, Dumas J, Adnane L et al (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245–255
10. Demetri GD, Reichardt P, Kang Y-K et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295–302
11. US Food and Drug Administration (2013) FDA news release: FDA approves Stivarga for advanced gastrointestinal stromal tumors. US FDA. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm340958.htm. Accessed Aug 2014
12. ® approved for the treatment of patients with gastrointestinal stromal tumors in Japan. http://press.healthcare.bayer.com/en/press/auth/news-details-page.php/15176/2013-0432. Accessed Aug 2014
13. Kim HS, Hong MH, Kim K et al (2011) Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology 80:395–405
14. Uemura H, Shinohara N, Yuasa T et al (2010) A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 40:194–202
15. Ueda T, Uemura H, Tomita Y et al (2013) Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized phase 3 AXIS trial. Jpn J Clin Oncol 43:616–628
16. Agaram NP, Besmer P, Wong GC et al (2007) Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res 13:170–181
17. Demetri GD, Jeffers M, Reichardt P et al (2013) Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs. placebo in TKI-refractory metastatic GIST. Cancer Res 73:LB–295 (abstract)
18. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34
19. Yoshino T, Komatsu Y, Yamada Y et al (2014) Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Invest New Drugs (Epub ahead of print, 12 Sep 2014)
20. Li J, Qin S, Yau T et al (2014) CONCUR: a randomized, double-blind, placebo-controlled phase 3 study of regorafenib monotherapy in Asian patients with previously treated metastatic colorectal cancer (mCRC). Ann Oncol 25(Suppl 2):ii114–ii115